Gilead pads out its antiviral portfolio with more acquisitions - The Pharma Letter

Gilead pads out its antiviral portfolio with more acquisitions  The Pharma Letter

Gilead Sciences (Nasdaq: GILD) today announced today that it has licensed three pre-clinical antiviral programs, including investigational agents with the ...